Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts
Purpose: The study aimed to investigate the associations between impaired spirometry such as obstructive pattern and preserved ratio impaired spirometry (PRISm) and occurrent cardiovascular events and deaths in patients with acute myocardial infarction. Patients and Methods: %pred ≥80. Follow-up data were obtained from national registers or follow-up visits. Multivariable Cox regression was used to analyze the associations of obstructive pattern and PRISm with the incidence of acute ischemic cardiovascular events or major adverse cardiovascular events (MACE), respectively, within one year. Results: Obstructive pattern was found in 95 (18%), PRISm in 192 (37%) and normal spirometry in 230 (45%) patients. A cardiovascular event occurred in 21 (4%) and MACE in 28 (5%). Compared with normal spirometry, PRISm was independently associated with both new cardiovascular events (HR (95% CI) 3.44 (1.07-11.0)) and MACE (4.94 (1.63 to 15.0)), and obstructive pattern with MACE (3.87 (1.08-13.8)). Further adjustment for cardiac or COPD treatment did not substantially change the results. Conclusion: About half of patients with acute myocardial infarction and a ≥10 pack-year smoking history have abnormal spirometry findings. Both obstructive pattern and PRISm are independently associated with increased risk for MACE within one year. We suggest that spirometry should be considered as a routine assessment in patients with smoking history and recent myocardial infarction.
Authors
- J Oldgren
- Hannah McMellon
- Pontus Andell (ORCID: https://orcid.org/0000-0002-2759-1379)
- Jad El Khoury
- Christian Reitan (ORCID: https://orcid.org/0000-0002-6460-4853)
- Robert F. Storey (ORCID: https://orcid.org/0000-0002-6677-6229)
- Tomas Jernberg (ORCID: https://orcid.org/0000-0003-1695-379X)
- Bethany Moyle
- Anna Björkenheim (ORCID: https://orcid.org/0000-0002-4288-3310)
- Sofia Sederholm Lawesson (ORCID: https://orcid.org/0000-0002-4776-0870)
- Raulin Surujbally
- Axel Åkerblom (ORCID: https://orcid.org/0000-0002-0458-2736)
- William A. Parker (ORCID: https://orcid.org/0000-0002-7822-8852)
- Moman A. Mohammad (ORCID: https://orcid.org/0000-0003-4242-9801)
- Kyriakos V. Konstantinidis
- Johan Lindbäck
- N Elamin
- D Erlinge
- R Hofmann
- Josefin Sundh
- Christer Janson
- Stefan James
- Mehul Patel
Institutions
- Linköping University (SE)
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Lund University (SE)
- Örebro University (SE)
- Karolinska Institutet (SE)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- AstraZeneca (Switzerland) (CH)
- Örebro University Hospital (SE)
- AstraZeneca (Poland) (PL)
- Skåne University Hospital (SE)
- AstraZeneca (Spain) (ES)
- Linköping University Hospital (SE)
- University of Sheffield (GB)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2026-04-01
- DOI
- https://doi.org/10.2147/copd.s580301
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca